Loading…
Aktis Oncology, Inc. is projected to rise to $47.66 by 2027, a +71% move from its current price of $27.88. AKTS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $26.62 | $27.87 | $29.18 | -0.02% |
| Jul 14 | $26.11 | $27.87 | $29.74 | -0.05% |
| Jul 15 | $25.73 | $27.86 | $30.17 | -0.07% |
| Jul 16 | $25.41 | $27.85 | $30.53 | -0.10% |
| Jul 17 | $25.13 | $27.85 | $30.86 | -0.12% |
| Jul 18 | $24.88 | $27.84 | $31.15 | -0.15% |
| Jul 19 | $24.65 | $27.83 | $31.43 | -0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $24.65 | $27.83 | $31.43 | -0.17% |
| Week 2 | $23.40 | $27.78 | $32.99 | -0.34% |
| Week 3 | $22.47 | $27.74 | $34.23 | -0.51% |
| Week 4 | $21.72 | $27.69 | $35.31 | -0.68% |
| Week 5 | $21.07 | $27.64 | $36.27 | -0.85% |
| Week 6 | $20.49 | $27.59 | $37.16 | -1.02% |
| Week 7 | $19.97 | $27.55 | $37.99 | -1.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aktis Oncology, Inc. is a clinical-stage oncology company focused on the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company’s lead product candidates include [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform in ongoing Phase 1b clinical trials for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelical cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
Aktis Oncology has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc.
in April 2020. Aktis Oncology was incorporated in 2020 and is headquartered in Boston, Massachusetts.
Aktis Oncology, Inc. (AKTS) is trading at $28.69 per share with a market capitalization of $1.59B. It is ranked 2221 among listed equities. The 30-day technical picture shows bullish sentiment, RSI14 at 60, and a 50-day simple moving average of $22.02, with support at $18.58 and resistance at $32.23.
The thirty-day price range runs from $20.82 to $39.53. Annualized volatility is 90%.
A major floor 54.9% below — a decisive break under it would weaken the trend.
The nearest floor, 33.4% below — buyers have tended to step in here.
The nearest ceiling, 15.6% above — a clean break opens room to run.
A major ceiling 43.0% above — clearing it would confirm fresh momentum.
Key AKTS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AKTS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $27.83 | Buy | $28.39 | Sell |
| MA 10 | $29.36 | Sell | $28.33 | Sell |
| MA 20 | $26.88 | Buy | $26.90 | Buy |
| MA 50 | $22.37 | Buy | $23.80 | Buy |
| MA 100 | $20.58 | Buy | $22.10 | Buy |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 56.02 | Neutral |
| Stoch RSI (14) | 8.13 | Buy |
| CCI (20) | 21.34 | Neutral |
| Williams %R (14) | -58.47 | Info |
| MACD (12,26,9) | -0.28 | Sell |
| ROC (12) | 3.22 | Buy |
| Bollinger %B (20,2) | 0.57 | Neutral |
| Stochastic %K (14) | 41.53 | Neutral |
| TRIX (15) | 1.54 | Buy |
| Awesome (5,34) | 3.91 | Buy |
| Ultimate (7,14,28) | 41.93 | Neutral |
| Momentum (10) | -3.27 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 27.44 | Buy |
| ADX (14) | 25.21 | Buy |
| ATR (14) | 1.25 | Info |
Near-term technical picture remains bullish with RSI14 at 60. The stock is trading above the 50-day SMA of $22.02, which supports a constructive near-term bias. The 30-day range is $20.82 to $39.53, with near-term support at $18.58 and resistance at $32.23.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $15.19 | $27.88 | $42.30 | 0% | Neutral | |
| $32.57 | $47.66 | $75.60 | +71% | Bullish | |
| $41.62 | $66.25 | $113.45 | +138% | Bullish | |
| $39.26 | $67.27 | $122.07 | +141% | Bullish | |
| $43.39 | $79.61 | $151.48 | +186% | Bullish | |
| $46.98 | $92.01 | $182.31 | +230% | Bullish | |
| $44.16 | $92.18 | $189.29 | +231% | Bullish | |
| $61.28 | $136.17 | $288.67 | +388% | Bullish | |
| $76.71 | $170.47 | $371.99 | +511% | Bullish | |
| $81.60 | $181.34 | $406.34 | +550% | Bullish | |
| $149.79 | $332.86 | $765.57 | +10.9x | Bullish | |
| $263.10 | $584.67 | $1,344.73 | +20.0x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $15.19 | $27.88 | $34.56 | +0.00% |
| August 2026 | $21.51 | $26.48 | $34.21 | -5.02% |
| September 2026 | $21.74 | $27.26 | $36.15 | +2.96% |
| October 2026 | $23.01 | $29.32 | $39.73 | +7.55% |
| November 2026 | $22.84 | $29.51 | $40.71 | +0.64% |
| December 2026 | $23.05 | $30.17 | $42.30 | +2.24% |
Click any year to see its month-by-month AKTS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, AKTS could reach as high as $42.30, with a base case around $27.88 and support toward $15.19 — roughly 0% from $27.88. Price action looks broadly range-bound.
Expect AKTS to range from $32.57 to $75.60 through 2027. The $47.66 average target implies a +71% move from current prices. That is up +71% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The AKTS price prediction for 2028 points to an average of $66.25 (low $41.62, high $113.45) — a potential gain of +138% on today's $27.88. Momentum favours further upside here.
In 2029, AKTS is projected to trade between $39.26 and $122.07, averaging $67.27 — a potential gain of +141% from today's $27.88. That is up +2% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Aktis Oncology, Inc.'s 2030 outlook centres on $79.61, within a $43.39 to $151.48 range. That is up +18% on the projected 2029 average. That marks a +186% change versus current levels. Momentum favours further upside here.
By 2031, AKTS could reach as high as $182.31, with a base case around $92.01 and support toward $46.98 — roughly +230% from $27.88. Buyers look set to stay in control over this stretch.
Expect AKTS to range from $44.16 to $189.29 through 2032. The $92.18 average target implies a +231% move from current prices. That is up 0% on the projected 2031 average. Momentum favours further upside here.
The AKTS price prediction for 2033 points to an average of $136.17 (low $61.28, high $288.67) — a potential gain of +388% on today's $27.88. Buyers look set to stay in control over this stretch.
In 2034, AKTS is projected to trade between $76.71 and $371.99, averaging $170.47 — a potential gain of +511% from today's $27.88. That is up +25% on the projected 2033 average. Momentum favours further upside here.
Aktis Oncology, Inc.'s 2035 outlook centres on $181.34, within a $81.60 to $406.34 range. That is up +6% on the projected 2034 average. That marks a +550% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, AKTS could reach as high as $765.57, with a base case around $332.86 and support toward $149.79 — roughly +10.9x from $27.88. Momentum favours further upside here.
Expect AKTS to range from $263.10 to $1,344.73 through 2050. The $584.67 average target implies a +20.0x move from current prices. That is up +76% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in AKTS today (≈ 35.868006 AKTS) could be worth
$20,970.82
+$19,970.82 (+1997%) by 2050 · US Dollar
Based on the average projected AKTS price of $584.67 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AKTSwould be worth at today's price.
$1,000 invested in AKTS on Jan 9, 2026 (≈ 44.642858 AKTS) would be worth
$1,244.64
+$244.64 (+24.5%) today · 1.24× · US Dollar
Based on a AKTS entry price of $22.4 vs. today's $27.88.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $31.76 | $877.83 | -12.2% |
| 1 month ago | $18.58 | $1,500.54 | +50.1% |
| 3 months ago | $16.88 | $1,651.66 | +65.2% |
| 6 months ago | $21.75 | $1,281.84 | +28.2% |
| All time ago | $22.4 | $1,244.64 | +24.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AKTS forecast.
Our base-case forecast reaches $56.00 around 2028.
Implied market cap at $56.00: $2.99B
The multi-year forecast shows a path of rising average prices and bullish sentiment over time. In 2026, the avg is $28.69 with ROI of 0 and sentiment NEUTRAL. In 2027, the avg is $50.26 with min $33.78, max $81.03, ROI 75.2%, sentiment BULLISH.
The forecast continues with rising averages into the late 2020s and 2030s, including 2030 with avg $82.21, min $43.22, max $160.06 and ROI 186.6% and bullish sentiment, followed by stronger levels in 2040 (avg $346.19, min $155.79, max $796.24, ROI 1106.7%) and 2050 (avg $599.67, min $269.85, max $1,379.25, ROI 1990.2%). The long-horizon outlook remains bullish across years 2027–2050, but these are estimates, not guarantees, and volatility is acknowledged by the high implied volatility in the data (annualized volatility 90%).
Tap a question to reveal the answer.
Avg $82.21, Min $43.22, Max $160.06, ROI 186.6%, Sentiment BULLISH. Note: These are estimates, not guarantees.
Forecasts show bullish sentiment in 2027, 2028, 2029, 2030 and beyond with rising avg prices and ROI up to 1990.2% by 2050, while 2026 is Neutral. These are estimates, not guarantees.
Yes. The forecasted max prices include $120.56 in 2028, $128.80 in 2029, and $160.06 in 2030, indicating $100 could be reached in 2028 or later.
Current price is $28.69 and market cap is $1.59B.
The 30-day range is $20.82 to $39.53, RSI14 is 60, sentiment is BULLISH, with support at $18.58 and resistance at $32.23.
Aktis Oncology, Inc. Community Discussion
0Share your Aktis Oncology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.